Acaida have been very cautious by back ending the US Trofinetide deal at the expense of significant royalties. Since that date there has been no new trials or studies that would change the risk profile Trofinetide and it's likelihood of FDA approval. I just see why Acadia would suddenly want to double down and by Neuren outright. Don't think that is on the cards IMO.
CR for Acadia, page-14
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.68 |
Change
0.070(0.51%) |
Mkt cap ! $1.763B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $13.85 | $13.51 | $1.039M | 75.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 99 | $13.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.68 | 74 | 4 |
View Market Depth
| Last trade - 12.03pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |